Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15096202 | 1.00 | CHRNB2 (0.33) | CHRNB2CHRNA7CHRNA4ALDH1A1TSHR | |
| SCHEMBL877918 | 1.00 | CHRNB2 (0.33) | CHRNB2CHRNA7CHRNA4ALDH1A1TSHR | |
| SCHEMBL15094488 | 1.00 | CHRNB2 (0.33) | CHRNB2CHRNA7CHRNA4ALDH1A1TSHR | |
| SCHEMBL15094487 | 1.00 | CHRNB2 (0.33) | CHRNB2CHRNA7CHRNA4ALDH1A1TSHR | |
| SCHEMBL10092278 | 0.89 | ALDH1A1 (0.31) | ALDH1A1TSHRMEN1CYP3A4MAPT | |
| SCHEMBL10092280 | 0.89 | ALDH1A1 (0.31) | ALDH1A1TSHRMEN1CYP3A4MAPT | |
| SCHEMBL3703449 | 0.80 | TSHR (0.36) | CHRNB2CHRNA7CHRNA4ALDH1A1TSHR | |
| SCHEMBL10092275 | 0.80 | TSHR (0.36) | CHRNB2CHRNA7CHRNA4ALDH1A1TSHR | |
| SCHEMBL15412875 | 0.80 | TSHR (0.36) | CHRNB2CHRNA7CHRNA4ALDH1A1TSHR | |
| SCHEMBL15423605 | 0.79 | TRPA1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3825312-A1 | INTERMEDIATES FOR PREPARING INHIBITORS OF HEPATITIS C VIRUS | Gilead Pharmasset LLC (US) | 2021-05-26 | — | — | EP | disclosed |
| US-10603318-B2 | Inhibitors of hepatitis C virus | GILEAD PHARMASSET LLC (US) | 2020-03-31 | — | — | US | disclosed |
| US-10335409-B2 | Inhibitors of hepatitis C virus | GILEAD PHARMASSET LLC (US) | 2019-07-02 | — | — | US | disclosed |
| EP-3492464-A1 | INTERMEDIATES FOR PREPARING INHIBITORS OF HEPATITIS C VIRUS | Gilead Sciences, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-3492464-A1 | INTERMEDIATES FOR PREPARING INHIBITORS OF HEPATITIS C VIRUS | Gilead Sciences, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20190008858-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2019-01-10 | — | — | US | disclosed |
| EP-3159345-B1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES INC (US) | 2019-01-09 | — | — | EP | disclosed |
| EP-2086982-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-08-29 | — | — | EP | disclosed |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2017-10-12 | — | — | US | disclosed |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2017-10-12 | — | — | US | disclosed |
| WO-2014008285-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
| WO-2014008285-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
| US-20130178413-A1 | HCV NS3 PROTEASE INHIBITORS | MSD ITALIA SRL (IT) | 2013-07-11 | — | — | US | disclosed |
| US-20130178413-A1 | HCV NS3 PROTEASE INHIBITORS | MSD ITALIA SRL (IT) | 2013-07-11 | — | — | US | disclosed |
| US-20130178413-A1 | HCV NS3 PROTEASE INHIBITORS | MSD ITALIA SRL (IT) | 2013-07-11 | — | — | US | disclosed |
| WO-2012040040-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20100099695-A1 | HCV NS3 Protease Inhibitors | MSD ITALIA S.R.L. (IT) | 2010-04-22 | — | — | US | disclosed |
| US-20100099695-A1 | HCV NS3 Protease Inhibitors | MSD ITALIA S.R.L. (IT) | 2010-04-22 | — | — | US | disclosed |
| US-20100099695-A1 | HCV NS3 Protease Inhibitors | MSD ITALIA S.R.L. (IT) | 2010-04-22 | — | — | US | disclosed |
| WO-2008057209-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099695-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | CHRNB2 4882/4885CHRNA7 4866/4885CHRNA4 4881/4885 |
| US-20130178413-A1 | HCV NS3 PROTEASE INHIBITORS | HAVCR2, CTSC, GTF3C3 | CHRNB2 4881/4885CHRNA7 4866/4885CHRNA4 4882/4885 |
| US-20190008858-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | CHRNB2 4833/4885CHRNA7 4685/4885CHRNA4 4845/4885 |
| US-10603318-B2 | Inhibitors of hepatitis C virus | HAVCR2, SLC10A1, GOT1 | CHRNB2 4833/4885CHRNA7 4685/4885CHRNA4 4845/4885 |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | CHRNB2 4833/4885CHRNA7 4685/4885CHRNA4 4845/4885 |
| US-10335409-B2 | Inhibitors of hepatitis C virus | HAVCR2, SLC10A1, GOT1 | CHRNB2 4833/4885CHRNA7 4685/4885CHRNA4 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.